Bupropion
Bupropion is an atypical antidepressant medication sold under the brand names include Wellbutrin, Aplenzin, and Zyban, and formerly Budeprion.[1][2][3] In addition to treating depression and severe pain, it is also used to treat seasonal affective disorder (SAD), and to reduce cravings in smoking cessation and drug addiction.[1][4]
Types[edit | edit source]
Bupropion is available in different forms, and may be combined with other drugs for particular uses, including
- Bupropion for smoking cessation, brand name Zyban
- Bupropion for major depression, brand name Wellbutrin[4]
Theory[edit | edit source]
Buproprion, like all antidepressants, does not address the underlying mechanisms of ME/CFS, so should not be regarded as a cure. It should be used only to reduce particular symptoms or treat a co-existing disorder (e.g. depression), and it is not a primary treatment for ME/CFS.[5]
ME/CFS patients may tolerate brand name bupropion better than generic versions due to sensitivities.[citation needed]
Evidence[edit | edit source]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Learn more[edit | edit source]
- Bupropion for depression and psychiatric use - Drugs.com
- Bupropion transdermal for pain - Medline Plus
See also[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 "Bupropion: MedlinePlus Drug Information". medlineplus.gov. Retrieved January 8, 2019.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedPMC2729622 - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedpatch - ↑ 4.0 4.1 https://www.drugs.com/bupropion
- ↑ Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02
